PYXS – pyxis oncology, inc. (US:NASDAQ)

News

Pyxis Oncology, Inc. (NASDAQ: PYXS) had its price target raised by analysts at Royal Bank of Canada from $7.00 to $10.00. They now have an "outperform" rating on the stock.
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Pyxis Oncology, Inc. (NASDAQ: PYXS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data [Yahoo! Finance]
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com